TISSUE REGENIX GROUP PLC — AGM Information 2014

Jun 27, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7912K

Tissue Regenix Group PLC

27 June 2014

Tissue Regenix Group Plc

("Tissue Regenix" or "the Company")

Result of AGM

YORK, 27 June, 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, hereby provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

For Further Information

Tissue Regenix Group Plc:                                                           +44 19 0443 5176

Antony Odell

Ian Jefferson

Jefferies International Ltd:                                                         +44 20 7029 8000

Simon Hardy

Harry Nicholas

Newgate Communications:                                                        +44 207 6806550

Alistair Kellie                                                                                   

Andrew Jones                                                                  

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSEMFDWFLSELM